NetworkNewsBreaks – Green Hygienics Holdings Inc. (GRYN) Enters Agreement with Leading Mexican Academic Research Institution to Advance ECS Research
Green Hygienics Holdings (OTCQB: GRYN), an innovative, technology-driven enterprise focused on the high standard cultivation and processing of industrial hemp and manufacturing of pharmaceutical-grade bioactive cannabinoids, announced that it partnered with Cinvestav, the Center for Research and Advanced Studies of the National Polytechnic Institute (Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional). The scientific research collaboration agreement is aimed at advancing R&D efforts through the characterization and development of cannabinoid-based products targeting endocannabinoid system (“ECS”) deficiencies in both animals and humans. Cinvestav is a leading Mexican multidisciplinary scientific research institution, ranking fourth among research centers in Latin America. In the announcement, company management noted it is confident in the collaboration on the development of new and efficacious products and believes that offering research-backed products is the fastest and most cost-efficient way to expand into new markets. “This research collaboration will be our first project under TruLife Biotech LLC, a Green Hygienics company focused on the development and advancement of innovative cannabinoid-based nutraceutical and skincare products and brands,” said Green Hygienics chief scientific officer Dr. Levan Darjania in the press release. “The collaboration with Cinvestav will augment ongoing efforts by both parties to identify and explore selected cannabinoids and terpenes in planned combinations that may act synergistically to protect against pain development and determine their potential efficacy as pain relievers against inflammatory and neuropathic pain. Therefore, the Company is building its collaborative model with academic institutions and will utilize its TruLife Biotech R&D platform to create proprietary and highly efficacious cannabinoid-based products.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Green Hygienics Holdings (OTCQB: GRYN), an innovative, technology-driven enterprise focused on the high standard cultivation and processing of industrial hemp and manufacturing of pharmaceutical-grade bioactive cannabinoids, announced that it partnered with Cinvestav, the Center for Research and Advanced Studies of the National Polytechnic Institute (Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional). The scientific research collaboration agreement is aimed at advancing R&D efforts through the characterization and development of cannabinoid-based products targeting endocannabinoid system (“ECS”) deficiencies in both animals and humans. Cinvestav is a leading Mexican multidisciplinary scientific research institution, ranking fourth among research centers in Latin America. In the announcement, company management noted it is confident in the collaboration on the development of new and efficacious products and believes that offering research-backed products is the fastest and most cost-efficient way to expand into new markets. “This research collaboration will be our first project under TruLife Biotech LLC, a Green Hygienics company focused on the development and advancement of innovative cannabinoid-based nutraceutical and skincare products and brands,” said Green Hygienics chief scientific officer Dr. Levan Darjania in the press release. “The collaboration with Cinvestav will augment ongoing efforts by both parties to identify and explore selected cannabinoids and terpenes in planned combinations that may act synergistically to protect against pain development and determine their potential efficacy as pain relievers against inflammatory and neuropathic pain. Therefore, the Company is building its collaborative model with academic institutions and will utilize its TruLife Biotech R&D platform to create proprietary and highly efficacious cannabinoid-based products.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
